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Burkholderia pseudomallei is the etiological agent of melioidosis. Because of the bac-
terium’s intrinsic resistance and propensity to establish latent infections, melioidosis ther-
apy is complicated and prolonged. Newer generation β-lactams, speciﬁcally ceftazidime,
are used for acute phase therapy, but resistance to this cephalosporin has been observed.
ThechromosomallyencodedpenA geneencodesaputativetwinargininetranslocase(TAT)-
secreted β-lactamase, and penA mutations have been implicated in ceftazidime resistance
in clinical isolates. However, the role of PenA in resistance has not yet been systematically
studied in isogenetic B. pseudomallei mutant backgrounds. We investigated the effects
of penA deletion, point mutations, and up-regulation, as well as tat operon deletion and
PenATAT-signal sequence mutations.These experiments were made possible by employ-
ing a B. pseudomallei strain that is excluded from Select Agent regulations. Deletion of
penA signiﬁcantly (>4-fold) reduced the susceptibility to six of the nine β-lactams tested
and ≥16-fold for ampicillin, amoxicillin, and carbenicillin. Overexpression of penA by single-
copy, chromosomal expression of the gene under control of the inducible Ptac promoter,
increased resistance levels for all β-lactams tested 2- to 10-fold. Recreation of the C69Y
and P167S PenA amino acid substitutions previously observed in resistant clinical isolates
increased resistance to ceftazidime by ≥85- and 5- to 8-fold, respectively. Similarly, a S72F
substitution resulted in a 4-fold increase in resistance to amoxicillin and clavulanic acid.
Susceptibility assays with PenA TAT-signal sequence and  tatABC mutants, as well as
Western blot analysis, conﬁrmed that PenA is aTAT secreted enzyme and not periplasmic
but associated with the spheroplastic cell fraction. Lastly, we determined that two LysR-
family regulators encoded by genes adjacent to penA do not play a role in transcriptional
regulation of penA expression.
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INTRODUCTION
Burkholderia pseudomallei, the etiological agent of melioidosis, is
a saprophytic Gram negative bacterium endemic to many trop-
ical and subtropical regions of the world although much of the
disease and its investigation has historically been conﬁned to
Northern Australia and regions of SE Asia, notably NE Thailand,
Singapore,andMalaysia(ChengandCurrie,2005;Wiersingaetal.,
2006; Currie et al., 2008). Partially because of its large genome
and diverse repertoire of metabolic functions B. pseudomallei can
survive hostile conditions and is resilient to many antimicrobial
agents, including antibiotics (Holden et al., 2004). This makes
choosing effective therapeutic strategies difﬁcult. In the past three
decadeseventhemosteffectivetreatmentcouldnotpreventamor-
talityrateof 74%(Whiteetal.,1989).Clinicaloutcomesimproved
steadily with implementation of new therapies but the real break-
through was achieved with the introduction of ceftazidime, an
extended-spectrum cephalosporin, which halved the mortality
rate compared to the traditional multidrug therapy of chlo-
ramphenicol, doxycycline, and trimethoprim–sulfamethoxazole
(White et al., 1989). Currently recommended melioidosis treat-
ment involves acute phase therapy followed by a lengthy eradi-
cation therapy. Initial parenteral therapy involves ceftazidime or a
carbapenemforaminimumof 10–14daysandlonger(4–8weeks)
for deep-seated infection. This regimen may be supplemented
with trimethoprim–sulfamethoxazole given orally for treatment
of patients with neurologic, prostatic, bone, or joint melioidosis.
Oral eradication therapy is trimethoprim–sulfamethoxazole with
or without doxycycline for at least 3–6months (Peacock et al.,
2008).
Because of the pivotal role that β-lactams play in the
acute phase treatment of melioidosis emergence of resistance,
though still considered rare, is of concern. It is believed that
B. pseudomallei’s resistance to β-lactams is due to chromosoma-
lly encoded β-lactamases (Livermore et al., 1987; Godfrey et al.,
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FIGURE 1 | Genomic organization of the B. pseudomallei penA
region.The genes and gene order are from sequenced strain K96243
(GenBank accession number NC_006351).The penA region encodes two
LysR-type regulators (BPSS0944 and BPSS0948) and a putative peptidase
(BPSS0945).The names of the mutants harboring gene deletion and
extents of deleted sequences are shown above each gene.The putative
PenA twin arginine translocase (TAT) signal sequence is shown below
the penA gene with the two conserved arginine residues shown in
red letters. Arrows indicate amino acid substitutions, R7K and R8A, in
theTAT-signal sequence and the names of the mutants are shown
next to the respective amino acids replacing the original
arginines.
1991). These include a number of Ambler Class A, B, and D
β-lactamasesthatareencodedbytheK96243andotherB.pseudo-
mallei genomes(Holdenetal.,2004).ThepenAgene(K96243gene
BPSS0946 found on chromosome II; Figure 1) encodes a Class A
β-lactamase (Cheung et al., 2002; Tribuddharat et al., 2003). This
geneispresentandexpressedinprototypeB.pseudomallei strains.
PenA confers resistance to numerous β-lactam antibiotics when
expressed in Escherichia coli (Cheung et al., 2002; Tribuddharat
et al., 2003) and several reports described a role of this enzyme in
acquiredceftazidimeresistanceinpatientstreatedwiththisantibi-
otic (Godfrey et al., 1991; Tribuddharat et al., 2003; Sam et al.,
2009).MutationsidentiﬁedinclinicalstrainsincludedaC69Ysub-
stitution leading to high-level ceftazidime resistance (Sam et al.,
2009), a P167S substitution leading to medium-level ceftazidime
resistance (Tribuddharat et al., 2003) and a S72F mutation that
led to resistance to clavulanic acid (Tribuddharat et al., 2003). A
Class D Oxa-57 β-lactamase has been studied in vitro but its role
in clinically signiﬁcant β-lactam resistance remains unclear (Keith
et al.,2005).
While B. pseudomallei PenA β-lactamase has been studied in
some detail, previously published reports suffered until recently
fromsomeunavoidableshortcomings.First,manymutationscon-
tributing to clinically signiﬁcant β-lactam resistance were iden-
tiﬁed in genetically largely intractable clinical isolates. Thus, it
remained unclear whether the mutations were solely responsible
for causing the observed resistance. Second, because methods for
genetic manipulation of B. pseudomallei were rather rudimen-
tary until recently, most studies involved expression of putative
β-lactamase enzymes in E. coli. Third, United States Select Agent
and recombinant DNA regulations, as well as dual use concerns,
do complicate studies of clinically signiﬁcant antibiotic resistance
mechanisms. To address shortcomings of previous studies, we
employedstate-of-the-artSelectAgent-compliantgeneticandbio-
chemical methods and a deﬁned genetic background of a Select
Agent excluded B. pseudomallei strain, where applicable, to study
the contribution of PenA to B. pseudomallei’s resistance to clini-
callysigniﬁcantβ-lactamantibiotics.Thestudiesalsorevealedthat
PenA is secreted via the twin arginine translocase system and that
its expression in prototype strains does not seem to be regulated
by local transcriptional regulators.
Table 1 | Burkholderia pseudomallei strains used in this study.
Strain Description Source
Strain 1026b-based mutants
1026b Clinical isolate, wild-type DeShazer et al. (1997)
Bp319 1026b  penA This study
Bp409 1026b  tatABC This study
Bp420 1026b  penA  tatABC This study
Bp343 1026b  BPSS0945 This study
Bp344 1026b  BPSS0944 This study
Bp349 1026b  BPSS0948 This study
Bp342 1026b PenA R7K This study
Bp421 1026b PenA R8A This study
Strain Bp82-based mutants
Bp82 1026b  purM Propst et al. (2010)
Bp82.3 Bp82 PenA C69Y This study
Bp82.4 Bp82 PenA S72F This study
Bp82.5 Bp82 PenA P167S This study
Bp82.11 Bp82  penA This study
Bp82.14 Kmr; Bp82:Tn7T-Ps12-FKM-lox-BPSS0944a This study
Bp82.15 Kmr; Bp82:Tn7T-Ps12-FKM-lox-BPSS0945 This study
Bp82.16 Kmr; Bp82:Tn7T-Ps12-FKM-lox-BPSS0948 This study
Bp82.21 Kmr; Bp82:Tn7T-LAC-FKM-penA +b This study
aCloned genes are transcribed from the constitutive B. thailandensis ribosomal
s12 gene promoter.
bCloned penA gene is transcribed from the IPTG-inducible E. coli lactose
operon/tryptophan hybrid promoter Ptac.
MATERIALS AND METHODS
BACTERIAL STRAINS AND GROWTH CONDITIONS
Burkholderia pseudomallei strains used in this study are listed
in Table 1. E. coli strains DH5α (Liss, 1987) and MACH1
(Invitrogen, Carlsbad, CA, USA) were used as general cloning
strains, and DB3.1 (Invitrogen) for cloning with Gateway Vec-
tors. RHO3 was used as a mobilizer strain for conjugation of
plasmids from E. coli to B. pseudomallei (López et al., 2009).
Bacterial strains were grown in Lennox LB (MO BIO Labo-
ratories, Carlsbad, CA, USA) or LB without salt (10g/L tryp-
tone and 5g/L yeast extract) at 37˚C. Antibiotics were used
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at the following concentrations: 100μg/mL ampicillin (Amp),
35μg/mL kanamycin (Km), and 15μg/mL zeocin (Zeo) for E.
coli and 1,000μg/mL Km and 2,000μg/mL Zeo for B. pseudo-
mallei. Antibiotics were purchased from Sigma (St. Louis, MO,
USA) except Zeo which was from Invitrogen. The  purM strain
Bp82 was grown in media supplemented with 0.6mM adenine
to ensure growth rates comparable to strain 1026b. RHO3 was
growninmediacontaining400μg/mLdiaminopimelicacid(DAP;
LL-, DD-, and meso-isomers; Sigma). Induction of gene expres-
sion from Ptac was achieved by adding 1mM isopropyl β-d-1-
thiogalactopyranoside (IPTG;Gold Biotechnology,St. Louis,MO,
USA) to growth media.
ISOLATION OF MUTANTS CONTAINING CHROMOSOMAL DELETION OR
POINT MUTATIONS
All deletion and allelic-exchange procedures were based on
pEXKm5 (López et al.,2009; plasmids used in this study are listed
in Table 2) and were performed using previously described proto-
cols. The desired chromosomal deletions were veriﬁed by colony
PCR (Choi et al., 2008).
For construction of penA deletion mutants, PCR with primers
1687+1712 (PCR primers and mutagenic oligonucleotides are
listed in Table 3) and Taq polymerase (New England BioLabs,
Ipswich,MA,USA)wasusedtoamplifya1,308-bpregioncontain-
ing the BPSS0946 (penA) gene from 1026b chromosomal DNA.
The gel-puriﬁed PCR fragment was cloned into the SmaI site of
pUCP20 to yield pPS2370. This plasmid was then cleaved with
NsiI+PmlI, blunt ended with T4 DNA polymerase, followed by
re-ligation.Thisproceduredeleteda291-bpNsiI−PmlIfragment
from the penA gene and resulted in pPS2549. A 1,339-bp PvuII
 penA fragment was excised from this plasmid and ligated into
the SmaI site of pEXKm5 to create pPS2550. This plasmid was
used to create Bp82.11 and Bp319 by transferring the plasmid-
borne deletion alleles to either Bp82 or 1026b, respectively, via
conjugation from RHO3.
For deletion of tatABC, splicing by overlap extension (SOE-
ing) PCR was employed for engineering of deletion constructs.
SOEing reactions consisted of separately amplifying two frag-
ments, one using an“internal”primer with overlapping sequence
with the internal primer from the other fragment. These bands
were gel puriﬁed and 50ng of each product was added to a new
PCR reaction where it underwent PCR for ﬁve cycles (95˚C for
60s, 54˚C 30s, and 72˚C for 60s). At this point, the two non-
overlapping primers were added and the reaction proceeded for
another 30 cycles. Using in-house puriﬁed Pfu polymerase and
primer sets 2018+2019 (amplifying a 537-bp tatA 5  fragment)
and 2020+2021 (amplifying a 501-bp tatC 3  fragment),a 1,038-
bpSOEingPCRproductwasgeneratedtodelete1,527bpfromthe
tatABC gene cluster. This PCR product was ligated into pGem-
T Easy (Promega; Madison, WI, USA) to create pPS2612. An
EcoRI fragment was rescued from this plasmid and inserted into
pEXKm5 to create pPS2617, which was used to create Bp409
and Bp420 by transferring the plasmid-borne deletions to either
1026b or Bp319 (1026b  penA), respectively. PCR using primers
2047+2048 was used to conﬁrm the deletion.
Other genes located in the penA region of the chromo-
some were deleted using a SOEing PCR strategy and pCR2.1
(Invitrogen) as TA cloning vector. The BPSS0944 deletion
construct was created using primer sets 2014+2015 and
2016+2017 to generate pPS2609, from which a BstXI frag-
ment was excised and inserted into the SmaI site of pEXKm5
to yield pPS2614. The BPSS0945 deletion construct was gen-
erated using primer sets 2010+2011 and 2012+2013 to cre-
ate pPS2610, from which an EcoRI fragment was excised and
inserted into the EcoRI site of pEXKm5 to yield pPS2615.
The BPSS0948 deletion construct was created using primer
sets 2006+2007 and 2008+2009 to generate pPS2611, from
which an EcoRI fragment was excised and inserted into
the EcoRI site of pEXKm5 to yield pPS2616. The plasmid-
borne deletion alleles were transferred to the B. pseudomallei
1026b genome which resulted in strains Bp343, Bp344 and
Bp349, respectively. Deletions were veriﬁed by colony PCR
using primer sets 2045+2446, 2041+2042 and 2043+
2044,respectively.
Chromosomal penA point mutations were engineered using
the QuikChange Multi Kit (Stratagene, La Jolla, CA, USA),
5 -phosphorylatedmutagenicoligonucleotides,andplasmidDNA
templates.Mutagenicoligonucleotide2075wasusedwithpPS2674
to create pPS2675 for the PenA C69Y mutation. A 736-bp EcoRI
fragment from pPS2675 was then ligated into the EcoRI site of
pEXKm5toconstructpPS2677.PlasmidpPS2712wascreatedasa
platformforothermutationsbyligatingtheNruI–HincIIcontain-
ing penA fragment from pPS2676 into the SmaI site of pEXKm5.
Employing pPS2712 template DNA, mutagenic oligonucleotides
2136 and 2137 were used separately to create pPS2721 and
pPS2722 carrying PenA P167S and PenA S72F substitutions,
respectively. Allelic exchange was carried out by conjugal transfer
of pPS2677 (C69Y), pPS2721 (P167S), and pPS2722 (S72F) from
RHO3 into Bp82. Mutations were veriﬁed by PCR amplifying and
sequencing the region containing the expected mutation. TAT-
signalsequencemutationsweregeneratedusingasimilarstrategy.
The R7K mutation was engineered using mutagenic oligonu-
cleotide 2022 and pPS2674 to create pPS2613. The 736-bp EcoRI
fragment from this plasmid was ligated into pEXKm5 to yield
pPS2618. The R7K allele contained on this fragment was trans-
ferred to the 1026b genome which created Bp342. The mutagenic
oligonucleotide2076wasusedwithpPS2674toengineerpPS2676
tocreateanR8Amutation.The736-bpEcoRIfragmentwasexcised
from this plasmid and ligated into pEXKm5 to create pPS2678.
The R8A allele contained on this fragment was transferred to the
1026b genome which created Bp421. The presence of the desired
pointmutationsonplasmidsandthegenomewasveriﬁedbyDNA
sequencing.
GENE COMPLEMENTATION AND OVEREXPRESSION USING
SINGLE-COPY, CHROMOSOMALLY INTEGRATED MINI-Tn7 VECTORS
The mini-Tn7 system was used for introducing site-speciﬁc, sta-
ble insertions into the B. pseudomallei genome for purposes of
gene complementation or overexpression (Choi et al., 2008). Tn7
transpositionwasachievedbytri-parentalmatinginvolvingRHO3
harboringthemini-Tn7 vector,RHO3containingthehelperplas-
mid pTNS3 and the B. pseudomallei recipient strain,as previously
described(Choietal.,2006).Integrationeventswereveriﬁedusing
primers Tn7L and either BPGLMS1, BPGLMS2, or BPGLMS3
www.frontiersin.org July 2011 | Volume 2 | Article 139 | 3Rholl et al. Burkholderia pseudomallei β-lactam resistance
Table 2 | Plasmids used in this study.
Designation Descriptiona Source
PLASMIDS FOR penA DELETIONAND OVEREXPRESSION
pUCP20 Apr; Broad host-range cloning vector West et al. (1994)
pEXKm5 Kmr; Allelic-exchange plasmid López et al. (2009)
pTNS3 Apr;Tn7 insertion helper plasmid Choi et al. (2008)
pUC18T-mini-
Tn7T-Km-LAC
Apr Kmr;Tn7 cassette vector with Ptac and lacIq for regulated expression of cloned genes This study
pPS2370 Apr; pUCP20 with a 1,308bp penA fragment (ampliﬁed with primers 1687+1712) inserted into SmaI site This study
pPS2549 Apr; pPS2370 with 291bp NsiI-PmlI fragment deleted from penA This study
pPS2550 Kmr; 1,339bp PvuII fragment from pPS2549 was inserted into the SmaI site of pEXKm5 This study
pPS2605 Apr Kmr; pCR2.1 with 1,230bp penA fragment (ampliﬁed with primers 2003+2005) This study
pPS2608 Apr Kmr; pCR2.1 with the 1,261bp penA fragment from pPS2605 (ampliﬁed with primers 2003+2004 to
modify the 5  region)
This study
pPS2627 Apr Kmr; pUC18T-mini-Tn7T-Km-LAC with the 1,266bp penA fragment from pPS2608 This study
PLASMIDS FOR penA PUTATIVE REGULATORY GENE DELETIONAND OVEREXPRESSION
pPS2609 Apr Kmr; 1,043bp SOEing PCR product using primer sets 2014+2015 and 2016+2017 was ligated into
pCR2.1
This study
pPS2610 Apr Kmr; 1,300bp SOEing PCR product using primer sets 2010+2011 and 2012+2013 was ligated into
pCR2.1
This study
pPS2611 Apr Kmr; 1,239bp SOEing PCR product using primer sets 2006+2007 and 2008+2009 was ligated into
pCR2.1
This study
pPS2614 Kmr; blunt ended 1,085bp BstXI fragment from pPS2609 ligated into SmaI site of pEXKm5 This study
pPS2615 Kmr; 1,316bp EcoRI fragment from pPS2610 ligated into EcoRI site of pEXKm5 This study
pPS2616 Kmr; 1,255bp EcoRI fragment from pPS2611 ligated into EcoRI site of pEXKm5 This study
pUC18-mini-Tn7T-
Gm-Gateway
Apr Gmr; mini-Tn7T-Gm with GATEWAY cassette. GenBank accession number AY737004
Choi et al. (2005)
pPS2735 Apr Kmr; pUC18T-mini-Tn7T-Km-FRT with Ps12 This study
pPS2737 Apr Kmr; Gateway-readyTn7 cassette vector with s12 promoter toward insert (KpnI-AfeI fragment containing
1,824bp Gateway cassette from pPS1612 ligated into pPS2735 between KpnI-StuI)
This study
pPS2745 Kmr; Nested PCR with primers 2015+2016, then 2155+2156 for 1,051bp fragment, cloned into
pENTR-SD-D-TOPO
This study
pPS2746 Kmr; Nested PCR with primers 2013+2010, then 2157+2158 for 1,056bp fragment, cloned into
pENTR-SD-D-TOPO
This study
pPS2747 Kmr; Nested PCR with primers 2009+2006, then 2159+2160 for 1,456bp fragment, cloned into
pENTR-SD-D-TOPO
This study
pPS2748 Apr Kmr; Gateway LR recombination reaction with pPS2737+pPS2745 This study
pPS2749 Apr Kmr; Gateway LR recombination reaction with pPS2737+pPS2746 This study
pPS2750 Apr Kmr; Gateway LR recombination reaction with pPS2737+pPS2747 This study
PLASMIDS FOR ENGINEERING OFTAT-SIGNAL SEQUENCE MUTATIONS
pPS2674 Apr Kmr; 740bp of the 5  region of penA gene ampliﬁed with primers 2010+2011 and cloned into pCR2.1 This study
pPS2613 Apr Kmr; Mutagenic primer 2022 substituted AAG for CGC at bases 19-21 of penA in pPS2674 to provide a
R7K substitution
This study
pPS2618 Kmr; 736bp EcoRI fragment from pPS2676 ligated into EcoRI of pEXKm5 This study
pPS2676 Apr Kmr; Mutagenic primer 2076 substituted GC for CG at bases 22-23 of penA in pPS2674 to provide a R8A
substitution
This study
pPS2678 Kmr; 736bp EcoRI fragment from pPS2676 ligated into EcoRI of pEXKm5 This study
PLASMIDS FOR ENGINEERING OF penA POINT MUTATIONS
pPS2675 Apr Kmr; Mutagenic primer 2075 mutated G to A at base 224 of penA to provide a C69Y substitution in
pPS2674 sequence
This study
pPS2677 Kmr; 736bp EcoRI fragment from pPS2675 ligated into EcoRI of pEXKm5 This study
pPS2712 Kmr; 1,094bp NruI-HincII fragment (entire penA) from pPS2370 ligated into the SmaI site of pEXKm5 This study
(Continued)
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Table 2 | Continued
Designation Descriptiona Source
PLASMIDS FOR ENGINEERING OF penA POINT MUTATIONS
pPS2721 Kmr; Mutagenic primer 2136 mutated C toT at base 517 of penA to provide a P167S substitution using
pPS2712 (pEXKm5-based)
This study
pPS2722 Kmr; Mutagenic primer 2137 C toT at base 233 of penA to provide a S72F mutation using pPS2712
(pEXKm5-based)
This study
PLASMIDS FOR tatABC DELETION
pPS2612 Apr; 1,038bp Soeing PCR product using primer sets 2018+2019 and 2020+2021 ligated into pGem-T Easy
(Promega, Madison, WI, USA)
This study
pPS2617 Kmr; 1,058bp EcoRI fragment from pPS2612 ligated into EcoRI of pEXKm5 This study
aAp, ampicillin; Km, kanamycin; Gm, gentamicin; Ps12, B. thailandensis ribosomal s12 gene promoter.
(Choi et al., 2008). All Tn7 mutants retained and used for fur-
ther experimentation had insertions at the glmS2-associated Tn7
insertion site.
For regulated penA expression and overproduction, the gene
was PCR ampliﬁed from pPS2370 using primers 2003+2005 and
Pfupolymeraseandthe1,230-bpPCRproductclonedintopCR2.1
(Invitrogen)toyieldpPS2605.Anoptimizedribosomebindingsite
(RBS)wasintroducedupstreamofpenAtocreatepPS2608byPCR
amplifying the penA region of pPS2605 with primers 2003+2004
and cloning the resulting 1,261bp fragment into pCR2.1. (The
amplicon was expected to be 1,295bp but the 5  end was trun-
catedby34bpwhichdidnotaffecttheintegrityof thepenA gene.)
An expression construct where penA was transcribed from the
inducible Ptac was obtained by cloning the 1,300-bp EcoRI frag-
ment from pPS2608 into pUC18T-mini-Tn7T-Km-LAC to create
pPS2627. The mini-Tn7 expression cassette from pPS2627 was
integrated into the genome of Bp82 at the glmS2-associated Tn7
integration site to form Bp82.21.
Constitutive expression of genes was achieved from chro-
mosomally integrated mini-Tn7 elements where the respec-
tive genes were transcribed from the B. thailandensis s12 pro-
moter (Choi et al., 2008). Nested PCR and Pfu polymerase
was used to PCR amplify BPSS0944 (primers 2015+2016 and
2155+2156),BPSS0945 (primers2010+2013and2157+2158),
and BPSS0948 (primers 2006+2009 and 2159+2160) from
strain 1026b genomic DNA. Each PCR began with three cycles
usingonlytheoutsideset(listedﬁrst)thentheinnerset(listedsec-
ond) was added for 30 more cycles. Inner primers were designed
for use with the pENTR/SD/D-TOPO cloning vector (Invitro-
gen, Carlsbad, CA, USA), which provides a RBS and direction-
ality, and created pPS2745, pPS2746, and pPS2747, respectively.
These plasmids then underwent the Gateway LR recombination
reaction (Invitrogen) with pPS2737, a mini-Tn7 vector which
enables constitutive expression from the B. thailandensis s12 pro-
moter (this promoter is directed toward the Gateway recombina-
tion cassette). To create pPS2737 the 1,824-bp Gateway-cassette-
containingtheKpnI-AfeIfragmentfrompUC18-mini-Tn7T-Gm-
GatewaywasligatedintopPS2735betweentheKpnIandStuIsites.
This Gateway-compatible mini-Tn7 element was used to create
pPS2748, pPS2749, and pPS2750 for constitutive expression of
BPSS0944, BPSS0945, and BPSS0948, respectively. The mini-Tn7
elements contained on these plasmids were individually inserted
attheglmS2siteofBp82withthehelpofpTNS3tocreateBp82.14,
Bp82.15, and Bp82.16.
MIC DETERMINATIONS
MICs were determined following general procedures recom-
mendedbytheClinicalandLaboratoryStandardsInstitute(2010).
However,since tatABC mutantsdonotgrowwellinthepresence
of saltsLBwithoutsaltwassubstitutedforMueller–HintonBroth.
MICs for ampicillin,carbenicillin,and BAL30072 (obtained from
Basilea Pharmaceutica, Basel, Switzerland) were determined by
thetwo-foldbrothmicrodilutiontechnique.Eteststripswereused
to determine MICs for amoxicillin, amoxicillin–clavulanic acid,
ceftazidime, imipenem, meropenem, and piperacillin according
to manufacturer’s instructions (AB BioMérieux, Marcy l’Etoile,
France). When needed, IPTG was added to media at a ﬁnal con-
centration of 1mM. The MICs were recorded after incubation at
37˚C for 18–24h.
QUANTIFICATION OF penA TRANSCRIPT LEVELS
Overnight cultures were subcultured into LB medium, grown to
an OD600nm of 0.5 and RNA was extracted with the RNeasy
Protect Bacteria Mini Kit (Qiagen, Valencia, CA, USA). cDNA
was synthesized using the SuperScript III First-Strand Synthesis
SuperMix for qRT-PCR (Invitrogen) and quantiﬁed using SYBR
GreenER qPCR SuperMix for iCycler Instruments (Invitrogen)
and the Bio-Rad iQ5 iCycler. The Bp23S-F+Bp23S-R primer set
was used for the 23s rRNA housekeeping gene for data normal-
ization and primers 2077+2078 were used to quantify the penA
transcript. Data analyses were performed using the iCycler soft-
ware. For induction studies with both wild-type and the mutants
with constitutive regulatory gene expression or deletion several
methodswereemployed.Forsaltstresstesting,strainsweregrown
inmediawith150mMNaClornoNaClaccordingtoPumiratetal.
(2009).Fortestinginductionbyβ-lactamsatsub-inhibitorylevels,
strains were subcultured into LB with 4-fold lower than MIC con-
centrationsofeitherceftazidimeorcarbenicillinuntilanOD600nm
of 0.5 was reached. Induction was also tested with fourfold higher
than MIC concentrations of ceftazidime,carbenicillin,imipenem,
or penicillin G (2,000μg/mL for penicillin G) by growing in LB
to an OD600nm of 0.5, then adding β-lactams and shaking for an
additional2hbeforeRNAextraction,accordingto Trépanieretal.
(1997).
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Table 3 | Primers used in this study.
Primer Sequencea,b,c,d Source
CLONING/DELETION
1687 5 -GGATCCGACGAGAGCTGATACGCTAG This study
1712 5 -AAGCTTATACCGGCATCGTTTCGCTG This study
2003 5 - GAATTCGATACCGGCATCGTTTCG This study
2004 5 -GATATCAGCCGTTGACTTAGTTGGTATTTCCGGAATATCATGCTGGTTCCGAATAA
TTTTGTTTAACTTTAAGAAGGAGATATAC
This study
2005 5 -ACTTTAAGAAGGAGATATACATGAATCATTCTCCGTTGCGC This study
2006 5 -CAATCTCGACGGAGCACG This study
2007 5 -CTTGAATGCCCTGCAGATCTTGGCCGCTACAGATACGACACb This study
2008 5 -AAGATCTGCAGGGCATTCAAG This study
2009 5 -GGTCATCGGGGACGAGTG This study
2010 5 -CGAATAGCGGATGAGATCG This study
2011 5 -GTTGTCTCGAGCATGAGCAAGGATTTTCTGACCGCTTACG This study
2012 5 -TTGCTCATGCTCGAGACAAC This study
2013 5 -AATGGGCGATACGGTAACAG This study
2014 5 -ACGAGCTTCCGAAATACACG This study
2015 5 -ATCGAGACGATTCGTTCAGC This study
2016 5 -CGAGCATCTCAAAATTCATCC This study
2017 5 -CGTGTATTTCGGAAGCTCGTTAATGGGCGATACGGTAACAG This study
2018 5 - ATGAATCACGACCCGAACTG This study
2019 5 - CTTGCTCTCGTCCTCTTCCTACGATCAGCAACACGATCAG This study
2020 5 - AGGAAGAGGACGAGAGCAAG This study
2021 5 - GACGAAGCTGCTGAACGTC This study
2041 5 -AGATACGGCATCGGATTGAC This study
2042 5 -GTCGCCGGCTGATTATTTC This study
2043 5 -GCAACGCTTGTTTCAATACG This study
2044 5 -GAAAGGCTCGGTCACGTTC This study
2045 5 -AATTCGTCACACGAACATGC This study
2046 5 -CGTCATTCCACCTTCCATTG This study
2047 5 -AGGAGGTCTACCACCTGCAC This study
2048 5 -TTTTGTTTGCCGCCATTC This study
2187 5 -CGAGCTTTCGCTGTCCTATC This study
2188 5 -CGTGATCTTCGTGTCCTTGAGTTGTGTCATTGCGCTTCTC This study
2189 5 -TCAAGGACACGAAGATCACG This study
2190 5 -CCGGCAATTGATCGAACTC This study
2191 5 -CGATCAACGTGATCTTCGTG This study
MUTAGENIC PRIMERS
2022 5 Phos/-GAATCATTCTCCGTTG AAG CGCTCGCTGCTCGTCGCAGC This study
2075 5 Phos/-GCTTTCCCGTTCT A CAGCACATCCAAGATGATGC This study
2076 5 Phos/-GAATCATTCTCCGTTGCGC GC CTCGCTGCTCGTCGCAGC This study
2136 5 Phos/-GCGCCGTGTTCAGCTCAG A CTCGCGGCGATCGAGC This study
2137 5 Phos/-AAAGCATCATCTTG A ATGTGCTGCAGAACTGG This study
REALTIME PCR PRIMERS
Bp23S-F 5 -GTAGACCCGAAACCAGGTGA Mima and Schweizer (2010)
Bp23S-R 5 -CACCCCTATCCACAGCTCAT Mima and Schweizer (2010)
2077 5 -GTTCTGCAGCACATCCAAGA This study
2078 5 -CGGTGTTGTCGCTGTACTGA This study
CLONING
1687 5 -GGATCCGACGAGAGCTGATACGCTAG This study
1712 5 -AAGCTTATACCGGCATCGTTTCGCTG This study
2010 5 -AGGCTGGCTGTACTTGAACG This study
2011 5 -CGGGCGATATTCTGATGTC This study
(Continued)
Frontiers in Microbiology | Cellular and Infection Microbiology July 2011 | Volume 2 | Article 139 | 6Rholl et al. Burkholderia pseudomallei β-lactam resistance
Table 3 | Continued
Primer Sequencea,b,c,d Source
TN7 INTEGRATION CONFIRMATION
Tn7L5  -ATTAGCTTACGACGCTACACCC Choi et al. (2005)
BPGLMS1 5 -GAGGAGTGGGCGTCGATCAAC Choi et al. (2008)
BPGLMS2 5 -ACACGACGCAAGAGCGGAATC Choi et al. (2008)
BPGLMS3 5 -CGGACAGGTTCGCGCCATGC Choi et al. (2008)
aBold indicates a newly generated restriction enzyme cleavage site.
bUnderline indicates overlapping sequence for SOEing PCR; a double underline indicates a ribosome binding site.
cItalics indicates introduced point mutations.
dPhos, 5
  phosphorylated oligonucleotide.
PROTEIN TECHNIQUES
Burkholderia pseudomallei cells were fractionated into periplasm
and spheroplastic protein fractions (cytosol and membranes)
using the PeriPreps™ Periplasting Kit (Epicentre Biotechnologies,
Madison,WI,USA) Cells were grown overnight and diluted 1:100
at37˚CinLBmediumwithoutNaCluntilanopticaldensityof 0.7
(600nm) was reached. The kit was used according to manufac-
turer’s protocols,including extended incubation times and higher
concentrationsof lysozyme(25μg/reaction),asrecommendedfor
hardier bacteria.
Escherichia coli Origami 2 DE3cells (Novagen, Madison, WI,
USA) expressing blapenA minus the ﬁrst 90 nucleotides (30 amino
acids) which encode the N-terminal signal sequence were sub-
cloned in the pET24a(+) vector (Stratagene) and used for protein
production and puriﬁcation. The PenA β-lactamase was extracted
from E. coli and puriﬁed using preparative isoelectric focusing.
After veriﬁcation of purity by SDS PAGE,3.0mg of PenA was sent
to New England Peptide (Gardner, MA, USA) where the poly-
clonal anti-PenA antibodies were raised in rabbits. The antibodies
were subsequently isolated from serum using a Protein G column
(GE Healthcare Life Sciences, Piscataway, NJ, USA) puriﬁcation
according to the manufacturer’s instructions.
ForWesternblots,proteinsampleswereseparatedonNuPAGE
®
4–12% Bis–Tris polyacrylamide gels (Invitrogen) alongside Pre-
cision Plus Protein Prestained Dual Color Standards (Bio-Rad,
Hercules,CA,USA).Agoatanti-RabbitIgGalkalinephosphatase-
conjugated antibody (Sigma) was used as a secondary antibody
and SIGMAFAST™ BCIP
®
/NBT tablets (Sigma) as a detection
reagent according to the manufacturer’s protocol.
RESULTS
THE ROLE OF OF penA IN β-LACTAM RESISTANCE
ToassesswhetherBp82anditsparent1026bcouldinterchangeably
be used for PenA characterization experiments, the susceptibili-
ties of these strains to various β-lactams were tested. Observable
differences in the susceptibilities of these two strains for any of
the beta-lactams and clavulanic acid tested (Table 4)w e r en o t
seen,thereby validating the use of Bp82 in experiments otherwise
not feasible under Select Agent regulations. Deletion of the penA
genefrom1026b(strainBp319)andBp82(strainBp82.11)caused
a signiﬁcant (≥4-fold) decrease in the susceptibilities for six of
nine β-lactams tested,and ≥16-fold for three of them (ampicillin,
amoxicillin, and carbenicillin; Table 4). Likewise, up-regulation
of penA by single-copy expression from the IPTG-inducible Ptac
(Bp82.21) signiﬁcantly increased the MIC for seven of the eight
β-lactams tested with meropenem showing only slight change.
(Amoxicillincouldnotbetestedastheresistancelevelforthewild-
type was already beyond detection.) Quantitative real time PCR
experiments showed that in the Ptac-penA strain (Bp82.21) penA
transcript levels were 36-fold higher when compared to transcript
levels observed in the wild-type strain (data not shown). This
increase in transcript levels corresponds to the observed increases
in resistance to all β-lactams. These experiments demonstrated
that although PenA is a clinically signiﬁcant β-lactam resistance
mechanism, it affects some β-lactams more than others. While
mutationsinpenA cansigniﬁcantlyaffecttheutilityof ceftazidime
andamoxicillin+clavulanicacid,theenzymehasalessereffecton
the activity of carbapenems and novel experimental drugs such as
BAL30072.
penA MUTATIONS ARE RESPONSIBLE FOR CLINICALLY SIGNIFICANT
CEFTAZIDIME AND AMOXICILLIN+CLAVULANIC ACID RESISTANCE
Previous studies identiﬁed several penA mutations in clinical and
laboratory isolates that led to clinically signiﬁcant ceftazidime
or clavulanic acid resistance. Speciﬁcally, a C69Y substitution
caused high-level ceftazidime resistance (Sam et al., 2009), a
P167S substitution medium-level ceftazidime resistance (Tribud-
dharat et al., 2003), and a S72F mutation resistance to clavu-
lanic acid (Tribuddharat et al., 2003). To assess whether these
mutations alone were sufﬁcient to cause the observed resistance
phenotypes, they were engineered into the penA gene of strain
Bp82 resulting in expression of a mutated PenA from the native
penA promoter. Susceptibility studies revealed that the C69Y
(Bp82.3) and P167S (Bp82.5) point mutations caused signiﬁ-
cant increases in ceftazidime resistance of ≥85- and 5- to 8-fold,
respectively(Table 4).Thesechangesareclinicallysigniﬁcantsince
the ceftazidime susceptibility, intermediate and resistance break-
points are deﬁned as MICs of ≤8, 16, and ≥32μg/mL, respec-
tively. The C69Y mutation sensitized strains to other β-lactams
such as amoxicillin, ampicillin, carbenicillin, and imipenem but
not amoxicillin+clavulanic acid, piperacillin, meropenem, and
BAL30072, whose MICs were already at low levels. The S72F
point mutation caused a four-fold increase in resistance to amox-
icillin+clavulanic acid in the resulting strain Bp82.4 and did not
cause any changes in susceptibility to other β-lactams.
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PenA IS SECRETED VIA THE TAT SYSTEM
Analysis of the amino-terminal PenA amino acid sequence
revealed the presence of a putative TAT-signal sequence indicat-
ing that it may be a TAT secreted protein (Figure 1). To test this
notion, the two signature arginine residues at positions 7 and 8
were changed to a lysine or alanine, respectively. MIC determi-
nations revealed that disruption of the TAT-signal sequence by
an R7K mutation (Bp342) did not affect PenA activity. This is
in accordance with previous studies which have shown that muta-
tionof theﬁrstargininetoalysinecaneitherhavelittleeffectorbe
completelyinhibitory,dependingontherestofthesignalsequence
(Stanleyetal.,2000).However,anR8Asubstitution(Bp421)com-
pletely abrogated PenA activity,consistent with PenA being a TAT
secretedenzyme.Thisnotionwasfurthersupportedbytheﬁnding
that a tatABC deletion mutant (Bp409) exhibited a susceptibility
proﬁlesimilartothoseoftheR8Asubstitution(Bp421)and penA
deletion strains (Bp319 and Bp82.11). As expected then,a  penA
 tatABC double mutant (Bp420) was most susceptible to PenA
substrates.
CELLULAR LOCALIZATION OF PenA
We next attempted to localize the PenA protein in the cell enve-
lopeusingWesternblotanalysisandpolyclonalα-PenAantibodies.
Usingthismethod,PenAcouldnotbelocalizedtotheperiplasmic
fraction but rather only to the spheroplastic fraction which con-
tains both cytosolic and membrane proteins. Multiple attempts at
isolation of PenA from the periplasmic fraction employing other
fractionation methods such as chloroform (Ames et al., 1984)o r
magnesium chloride (Imperi et al., 2009) extraction yielded the
same results. Western blot analysis of the spheroplastic fraction
(Figure 2) showed the mature 27kDa PenA protein is seen only
in an extract derived from wild-type 1026b (lane 5). In contrast,
the unprocessed 31kDa PenA protein was observed in extracts
from the R8A (lane 1) and  tatABC (lane 2) mutants Bp421 and
Bp409, respectively. A mixture of mature and unprocessed PenA
wasseenintheR7KmutantBp342extractwiththemajoritybeing
the mature protein (lane 3). As expected, no PenA protein was
observed in the extract from the  penA mutant Bp319 (lane 4).
ThisexperimentprovidesbiochemicalevidenceforPenAprocess-
ing only in 1026b and the R7K mutants, both of which secrete
activePenAviatheTATsystemasjudgedbyβ-lactamsusceptibility
assays. All other strains are susceptible to β-lactams.
LOCAL REGULATORS ARE NOT INVOLVED IN REGULATION OF penA
GENE EXPRESSION
As shown in Figure 1, the B. pseudomallei penA region encodes
two LysR-type transcriptional regulators and a putative peptidase.
Since chromosomal β-lactamase gene expression was shown to
be regulated by products of adjacent regulatory genes in several
bacteria, including B. cepacia (Trépanier et al., 1997), the struc-
tural genes encoding for these regulators were either deleted or
overexpressed and their effects on PenA transcription and activity
assessedbyeitherqRT-PCRorMICdeterminations.Carbenicillin
wasusedasa“sentry”β-lactamforassessingPenAactivitybyMIC
experimentsbecauseitisoneofthebestPenAsubstrates(Table 4).
MIC determinations showed that neither deletion of putative
regulators (Bp343 and Bp349 nor constitutive expression of the
regulators (Bp82.14 and Bp82.16) affected PenA activity (data
not shown). The same observations were made when ceftazidime
was used in susceptibility assays instead of carbenicillin. Likewise,
deletion (Bp344 and Bp82.31) or overexpression (Bp82.15) of the
putative peptidase gene upstream of penA h a dn oe f f e c to nP e n A
activity (data not shown). Lastly, since bacterial β-lactamase gene
expression can either be subject to substrate induction or inﬂu-
encedbyenvironmentalfactorssuchassalts(Pumiratetal.,2009),
MIC determinations were performed in the presence or absence
of substrate and salt. However, presence of ceftazidime, carbeni-
cillin, or high salt and the absence salt had no apparent effect on
β-lactamsusceptibilities.qRT-PCRassayssupportedtheMICdata,
with no change in penA expression levels observed between con-
trolsandstrainstreatedwithceftazidime,carbenicillin,imipenem,
penicillin G, or high salt (data not shown).
DISCUSSION
Thedatapresentedinthisstudyemployingisogeneticmutantsina
deﬁnedgeneticbackgroundconﬁrmthatPenAisamajorβ-lactam
resistance factor in B. pseudomallei. Increased expression of penA
conferred increased resistance levels to the majority of β-lactams
tested.Conversely,penA deletionresultedinsusceptibilitytoallβ-
lactams tested. Furthermore, clinically observed penA mutations
wereresponsibleforthealteredβ-lactamsubstratespectrumofthe
enzyme and consequently the new resistance proﬁle. Point muta-
tionsneartheactivesitearethemostcommonreasonforsubstrate
proﬁleshiftingbecausetheyaccommodatedifferentsidechainsof
various β-lactams by either changing the active site steric proper-
tiesorlocationsof theactualactiveresidues(DrawzandBonomo,
2010). Complete shifts in substrate proﬁles have been previ-
ously documented, such as with a mutant gram negative TEM-1
β-lactamase showing increased ceftazidime hydrolysis but
decreased activity against ampicillin (Venkatachalam et al.,1994).
The good news is that the B. pseudomallei C69Y PenA mutation
sensitizes the cell to other β-lactams thus possibly enabling new
therapeutic strategies. Additionally, our studies showed that of
all β-lactams tested meropenem is the only β-lactam not affected
FIGURE2|P e n Ai saT A Tsecreted protein. Spheroplastic proteins were
analyzed by Western blot using anti-PenA polyclonal antibodies.The arrows
point to the expected unprocessed (31kDa) and processed (27kDa) forms
of PenA. Lanes: 1, R8ATAT-signal sequence mutant; 2,  tatABC mutant; 3,
R7KTAT signal sequence mutant; 4,  penA mutant; 5, wild-type 1026b; M,
molecular weight markers (two proteins of the 10- to 250-kDa Precision
Plus Protein Dual Color Standards from Bio-Rad, Hercules, CA, USA).
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by penA mutations and overproduction, and thus the supe-
rior β-lactam antibiotic for melioidosis treatment with regard to
potentialemergenceof PenAβ-lactamasemutants.Unfortunately,
current costs limit use of meropenem in many clinical settings,
especially resource poor areas of the world (Cheng et al., 2004).
The mutants created and analyzed in this study did not pre-
cisely mimic previously documented mutants. In all cases, our
strains had an equal or lower resistance level. This may simply
be due to variations in MIC methodologies, which can change
the measurements signiﬁcantly (Wuthiekanun et al., 2005,o r
B.pseudomallei strainvariabilitythatmayaffectresistancepatterns
(Thibault et al.,2004). Using the S72F clinical mutant as an exam-
ple, two groups determined the MIC of the parental strain 392a
and its mutant, 392f. The ﬁrst group showed a 16-fold increase
inamoxicillin–clavulanicacidresistance(Godfreyetal.,1991)but
the other group only showed a two-fold increase (Tribuddharat
et al., 2003). These numbers are signiﬁcantly different from one
another. The susceptibilities observed with our isogenetic Bp82
derivatives fell between the two previously reported set of num-
bers at 4- to 5- fold.Another potential cause for inconsistency was
that some of the published experiments cloned the mutant penA
gene and expressed it in an unrelated bacterium, E. coli,f r o ma
high-copy number plasmid (Ho et al., 2002; Tribuddharat et al.,
2003). Our data showed that increased expression of penA from
a single-copy, chromosomally inserted expression element with a
strong inducible promoter can change the proﬁle from suscepti-
ble to resistant. A high-copy number plasmid will obviously lead
to higher gene expression and consequently high resistance lev-
els.Additionally,other cellular factors,including outer membrane
permeability,can affect the efﬁcacy of resistance mechanisms. For
the P167S mutation, Tribuddharat et al. (2003) showed a 16-fold
increase in ceftazidime resistance in B. pseudomallei, but only a
two-fold change in an E. coli strain expressing recombinant penA
genes.
Besides playing a crucial role in the export of virulence fac-
tors in many bacteria (De Buck et al., 2008), the TAT system
has previously been shown to be required for the export of
β-lactamases in Mycobacterium smegmatis (McDonough et al.,
2005). Through deletion of the tatABC operon and mutation
of a crucial arginine residue of the putative TAT-signal sequence
of B. pseudomallei PenA, we showed that PenA is indeed a TAT
secreted enzyme. The exact cellular location of PenA β-lactamase
could not be pinpointed. Various periplasmic extraction tech-
niques failed to localize the enzyme to the periplasm but rather
indicated that it is localized in the spheroplastic compartments
of the cell which encompasses the cytosol and the membranes.
Since a secreted enzyme is unlikely to be localized in the cytosol
this experimental evidence points to the fact that PenA may be a
membrane-associated enzyme. This is in agreement with earlier
ﬁndings by Livermore et al. (1987) who demonstrated that after
sonication and centrifugation, the vast majority of β-lactamase
activity was present in the membrane fraction. Membrane associ-
ation of β-lactamases is not common but has been documented.
The ﬁrst account of a membrane-associated β-lactamase in Gram
negative bacteria was from work with Moraxella catarrhalis
(Bootsma et al., 1999). In this case it was hypothesized that
the gene was a lipoprotein of Gram positive origin, as mem-
brane association in Gram positive bacteria had been previously
observed. This is unlikely the case for PenA because penA has
70% GC content, comparable to the overall genome (68%).
How B. pseudomallei PenA could become membrane associated
is unclear since there is no evidence of the enzyme being a
lipoprotein.
Further evidence for TAT secretion was obtained by analyz-
ing the PenA processing. Tullman-Ercek et al. (2007) describe
the processing of TAT-signal sequences and the cleavage of
their amino-termini upon passing through the inner mem-
brane, using MdoD as an example. The authors describe a
hydrophobic region before the processing site determined to be
an AXA motif. A comparative analysis of the amino-termini
of MdoD (MDRRRFKGSMAMAAVCGTSGASLFSQAAFA) and
PenA (MNHSPLRRSLLVAAISTPLIGACAOLRGQAKNVAAA) at
http://expasy.org/tools/protscale.html using the Kyte and Doolit-
tle hydrophobicity algorithm revealed that the two sequences
exhibited a similar hydrophobicity proﬁle and comparable pre-
dicted processing sites (underlined AFA in MdoD and AAA in
PenA). Using this information, we calculated that the molecular
mass of PenA changes from 31 to 27kDa after processing. Bands
corresponding to these sizes were seen observed using Western
blot analysis (Figure 2).
Some β-lactamase genes require LysR regulatory factors for
expression, with or without a β-lactam inducer. Trépanier et al.
(1997) showed that the penA gene from B. cepacia was regu-
lated by a LysR-family regulator encoded by the divergently tran-
scribed penR gene when expressed from plasmids in E. coli.P e n A
β-lactamase gene expression was not only regulated by PenR but
was also inducible in the presence of imipenem in this system.
A gene, BPSS0948, homologous to B. cepacia penR is found in
B. pseudomallei downstream of penA (Figure 1). An addi-
tional LysR-family regulator encoding gene, BPSS0944, is located
upstream of penA, but it has less sequence homology to penR
and is separated from penA by a putative peptidase gene.
Our analyses involving gene deletions, induction experiments,
as well as growing cells under conditions such as salt stress
(Pumirat et al., 2009 that may trigger β-lactamase induction
showed that neither the LysR-type regulators BPSS0944 and
BPSS0948 nor the putative peptidase encoded by BPSS0945
are involved in regulation of penA expression in B. pseudo-
mallei strain 1026b, at least not under the experimental con-
ditions employed during these studies. Although many chro-
mosomal β-lactamases are inducible, others are constitutively
expressed (Neu and Chin, 1985; Jacoby and Bush, 2005).
When multiple β-lactamases are present in a bacterial strain,
they can be subject to complex regulation, including co-
regulation with penicillin binding protein 2 (Hackbarth and
Chambers, 1993; Naas et al., 1995). In this context it is
noteworthy that by analysis of clinical strains obtained from
patients that failed ceftazidime therapy and studies of recre-
ated 1026b-based mutants we and others recently identiﬁed
deletion of a B. pseudomallei PBP3 homolog as a mecha-
nism causing high-level ceftazidime resistance (Chantratita et al.,
unpublished observations).
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Deﬁnition of the molecular basis of resistance mechanisms for
clinically signiﬁcant β-lactams forms the basis for design of diag-
nostic tools that allow rapid detection of emergence of resistance
and thus redirection (clinical settings) or initiation (biodefense)
of proper melioidosis therapy or prophylaxis.
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